EGFR and colorectal carcinoma: In addition to anti-EGFR antibody drugs, bevacizumab [14, 15], an anti-vascular endothelial cell growth factor antibody drug, and regorafenib [16], a multikinase inhibitor, are standard treatments for patients with unresectable advanced or recurrent CRC.